American Ginseng for Blood Sugar
American ginseng is the root of Panax quinquefolius, a plant native to eastern North America. It is a different species from Asian ginseng (Panax ginseng), and the two have been tested separately. In several small randomized trials, American ginseng taken before a glucose drink lowered the rise in blood sugar that followed, and one batch had no effect at all. In one 8-week trial of 24 people with type 2 diabetes, an extract added to their usual treatment lowered hemoglobin A1C (HbA1c), a blood test that reflects average blood sugar over the previous two to three months, by 0.29% compared with placebo.
Evidence base: small and short. The research records behind this page hold six single-occasion studies, each in 10 to 13 adults without diabetes (one of them also tested 9 adults with type 2 diabetes), three reports of 8 to 12 weeks in people with type 2 diabetes taking American ginseng extract, two 12-week trials of American ginseng combined with another ingredient, and pooled analyses that mix ginseng species. Two pooled analyses found a fall in fasting blood sugar and a third found none, and none of the three found a significant change in HbA1c overall. No trial lasted longer than 12 weeks.
Table of Contents
What the Plant Is and How It Has Been Used
American ginseng is a slow-growing woodland plant, and the root is the part used. The trials on this page gave it as ground root in capsules or as an extract. One study compared root from five farms in Ontario, Canada (PMID 18066131).
The word "ginseng" covers more than one plant, and the research keeps them apart:
- American ginseng is Panax quinquefolius. It is the subject of this page.
- Asian ginseng is Panax ginseng. Korean red ginseng is the root of this Asian species, steamed and dried. A 2011 systematic review looked at red ginseng alone and its findings, given below, are different from those for American ginseng (PMID 22139546).
Each study on this page is labelled with the species it used. This matters most for the pooled analyses, which combine trials of the whole Panax genus (the plant group that holds both species) into one result (PMID 25265315).
The authors of a trial published in 2000 described ginseng as one of the most widely used herbs and noted that the use of herbal medicine had grown considerably despite a lack of medical evidence for its effects (PMID 10761967). A 2012 review called American ginseng the best studied of the herbal preparations reported to have modest short-term effects on blood sugar (PMID 23390846).
The research records behind this page are clinical and laboratory papers. None of them describes the plant's traditional use for diabetes, so no such history is given here. The site's general ginseng page covers the history of both species.
Active Compounds and How They Act
The compounds studied most are the ginsenosides, a family of plant chemicals of the saponin type. A 2015 trial report calls them the proposed active constituent of ginseng for lowering blood sugar after a meal, and adds that the proportion of total and specific ginsenosides that works remains unknown (PMID 25446600).
Ginsenosides fall into two chemical groups, the protopanaxadiol group and the protopanaxatriol group, and individual ginsenosides carry short names such as Rb1 and Rg1. Researchers describe a root by its total ginsenoside content and by the ratios between these groups (PMID 12571655). Extracting root with alcohol changes that profile: higher alcohol concentrations give higher yields of total ginsenosides and shift the proportions of the individual ones (PMID 25446600).
What the research reports about how it acts
A 2012 review states that American ginseng improves blood sugar control in type 2 diabetes by raising insulin levels after a meal and lowering the blood sugar response to the meal (PMID 23390846). Insulin is the hormone that moves glucose out of the blood and into cells.
The insulin measurements made in healthy adults, described in the trials below, do not all point that way. In one study insulin after a glucose drink was lower with American ginseng than with water (PMID 18066131). In another, a batch with a low ginsenoside content changed neither blood sugar nor insulin, and its authors wrote that the ginsenoside profile might play a role and that the involvement of other components cannot be ruled out (PMID 12571655).
What Human Trials Found
The human research comes in three kinds: tests of a single amount taken before a glucose drink, trials of 8 to 12 weeks in people with type 2 diabetes, and pooled analyses that combine many trials.
Single amounts taken before a glucose drink
In these tests a person swallows ginseng or a placebo, then drinks a measured amount of glucose, and blood sugar is measured over the next 90 to 120 minutes. The result is often given as the area under the curve, a single number for how high blood sugar rose and how long it stayed up.
Randomized trial, 2000, American ginseng, 10 adults without diabetes and 9 with type 2 diabetes. On four occasions the participants took 3 g of American ginseng or placebo capsules, either 40 minutes before or together with a 25-g glucose drink. In the people with type 2 diabetes, ginseng lowered the blood sugar rise at both timings (P < .05): the area under the curve was 19% ± 22% lower when ginseng was taken 40 minutes before and 22% ± 17% lower when it was taken with the drink. In the people without diabetes, the reduction was 18% ± 31% when ginseng was taken 40 minutes before, and there was no difference from placebo when it was taken with the drink (PMID 10761967).
The timing of the dose
Two further randomized trials in adults without diabetes varied the timing.
Randomized crossover trial, 2001, American ginseng, 12 healthy adults. Each person received 16 treatments: placebo or 1, 2 or 3 g of American ginseng at 40, 20, 10 or 0 minutes before a 25-g glucose drink. Blood sugar was lower than with placebo only when the ginseng was taken 40 minutes before the drink. Taken 20, 10 or 0 minutes before, it had no effect (PMID 11273850).
Randomized trial, 2000, American ginseng, 10 adults without diabetes. On 12 occasions the participants took placebo or 3, 6 or 9 g of ground root at 40, 80 or 120 minutes before a 25-g glucose drink. All three amounts lowered the blood sugar rise, and taking the root earlier than 40 minutes before the drink added nothing further (PMID 11194526).
The chart shows the pattern reported by the three trials above. One later batch, described below, had no effect even at 40 minutes.
The size of the dose
In the 2001 trial, 1, 2 and 3 g all lowered blood sugar over the last 45 minutes of the test compared with placebo (P < 0.05), with no significant difference between the amounts. The reductions in the area under the curve were 14.4 ± 6.5%, 10.6 ± 4.0% and 9.1 ± 6% for 1, 2 and 3 g. The authors described the effect as dependent on timing and not on dose (PMID 11273850).
In the 2000 trial of larger amounts, the reductions in the area under the curve were 26.6% with 3 g, 29.3% with 6 g and 38.5% with 9 g. At the 60-minute reading, 9 g lowered blood sugar more than 3 g (p < 0.05). The authors' conclusion was that 3, 6 and 9 g improved glucose tolerance similarly (PMID 11194526).
One batch with no effect, and differences between batches
Randomized single-blind trial, 2003, American ginseng, 12 adults without diabetes. Result: no effect. The participants took 6 g of a different batch of American ginseng or placebo 40 minutes before a 75-g oral glucose tolerance test, the standard glucose drink test. The ginseng had no significant effect on blood sugar or insulin. This batch contained 1.66% total ginsenosides. The authors wrote that it "was unable to reproduce" the effect they had seen before, and gave its markedly lower ginsenoside content and ratios as a possible explanation (PMID 12571655).
Comparative study, 2007, American ginseng, 12 healthy adults. The participants took 9 g of root from each of five farms, in random order on five visits, and water alone on a sixth visit, 40 minutes before a 75-g oral glucose tolerance test. Compared with water, two batches lowered the blood sugar area under the curve, by 35.2% and 32.6%, and three lowered peak blood sugar, by 1.3, 1.2 and 1.1 millimoles per litre (mmol/L). The effects did not differ significantly from one batch to another. Averaged together, the five batches lowered peak blood sugar by 1.0 mmol/L, the blood sugar area under the curve by 27.7% and the insulin area under the curve by 23.8% compared with water. The authors reported that 40% of the batches did not lower blood sugar by the expected amount, whatever their saponin composition (PMID 18066131).
Randomized trial, 2015, American ginseng and Korean red ginseng, 13 healthy adults. The participants took 3 g of whole root or of a 30%, 50% or 70% alcohol extract of each species, or placebo, 40 minutes before a 50-g glucose drink. The abstract reports no difference between the ginseng preparations in their effect on blood sugar after the drink, and gives no blood sugar figure against placebo. Two preparations, the 50% extract of American ginseng and the 30% extract of Korean red ginseng, raised a calculated index of insulin sensitivity, which is how strongly the body responds to its own insulin, compared with placebo (p < 0.05) (PMID 25446600).
Trials of 8 to 12 weeks in type 2 diabetes
All of these trials added ginseng to the participants' usual diabetes treatment. None tested American ginseng in place of medication.
Double-blind randomized crossover trial, 2019, American ginseng extract, 24 adults with type 2 diabetes. Double-blind means that neither the participants nor the researchers knew who was taking what. Crossover means that every participant took both treatments in turn. The participants took 1 g of extract with each meal (3 g a day) or placebo for 8 weeks while keeping their original treatment, then switched after a break of at least 4 weeks. Their starting HbA1c was 7.1 ± 1.2%. Compared with placebo, the extract lowered HbA1c by 0.29% (p = 0.041) and fasting blood sugar by 0.71 mmol/L (p = 0.008). It also lowered systolic blood pressure, the upper number of a blood pressure reading, by 5.6 ± 2.7 mmHg (p < 0.001), and low-density lipoprotein (LDL) cholesterol ended 12.3 ± 3.9% lower. The authors wrote that larger studies are warranted to substantiate the findings (PMID 29478187).
Double-blind randomized placebo-controlled trial, 2013, American ginseng extract, 64 adults with type 2 diabetes and high blood pressure. The participants took 3 g of extract a day or placebo for 12 weeks on top of their usual treatment. The abstract reports no blood sugar result. Compared with placebo, the extract lowered a measure of artery stiffness by 5.3% (P = 0.041) and systolic blood pressure by 11.7% (P < 0.001), with no effect on diastolic blood pressure, the lower number (PMID 23973636).
A third report, a 12-week double-blind randomized safety study in 74 adults with type 2 diabetes, is described under Safety Findings and Interactions.
American ginseng combined with another ingredient
In two trials American ginseng was given together with something else, so the result belongs to the combination and cannot be assigned to the ginseng alone.
Randomized placebo-controlled crossover trial, 2018, American ginseng with a konjac-based fibre blend. Thirty-nine adults with type 2 diabetes were enrolled and 30 completed the study. For 12 weeks each they took the fibre blend with American ginseng, or a wheat bran control matched for fibre, while medication, diet and lifestyle were kept constant. They consumed 2.7 g of American ginseng a day. At week 12, HbA1c was 0.31% lower on the combination than on the control (p = 0.011), and LDL cholesterol was 8.3 ± 3.1% lower (p = 0.002) (PMID 28687934).
Randomized controlled trial, 2021, American ginseng with Korean red ginseng, 80 adults with type 2 diabetes and high blood pressure. This trial mixed the two species: the participants took 2.25 g a day of American ginseng combined with a Korean red ginseng enriched in the ginsenoside Rg3, or a wheat bran control, for 12 weeks on top of standard care. The main outcome was blood pressure measured over 24 hours, and systolic pressure fell by 3.98 ± 2.0 mmHg relative to control (p = 0.04). HbA1c fell by 0.35 ± 0.1% more than on control (p = 0.02) (PMID 34803424).
Pooled analyses, which mix ginseng species
A meta-analysis combines the results of many trials into one figure. The ones in these records pool trials of ginseng in general, so their results are not results for American ginseng alone.
- 2014 meta-analysis of the Panax genus, 16 randomized controlled trials of 30 days or longer, people with and without diabetes. Ginseng lowered fasting blood sugar by 0.31 mmol/L compared with control (95% confidence interval −0.59 to −0.03, P = 0.03). There was no significant effect on fasting insulin, HbA1c or a calculated measure of insulin resistance. A subgroup analysis planned in advance found a significant HbA1c difference in trials with separate treatment groups compared with crossover trials (0.22%, 95% confidence interval 0.06 to 0.37, P = 0.01). The authors called the effect on fasting blood sugar modest, noted that 67% of the trials ran for less than 12 weeks, and wrote that larger and longer trials with standardized preparations are warranted (PMID 25265315).
- 2016 meta-analysis, 8 randomized trials in type 2 diabetes or impaired glucose tolerance; the abstract does not state the species. There was no significant difference in HbA1c between ginseng and control (P = 0.355), and no difference in blood sugar after meals or in fasting insulin. Fasting blood sugar, insulin after meals and a measure of insulin resistance improved. Ginseng was ineffective at lowering fasting blood sugar in patients treated with glucose-lowering tablets or insulin (PMID 26871778).
- 2025 meta-analysis, 70 studies and 4506 participants; the abstract does not state the species. It found no significant effect of ginseng on blood sugar measures, blood pressure or blood fats. A separate dose-response analysis found a significant association between the ginseng dose and fasting blood sugar (P < 0.001) (PMID 40923100).
- 2011 systematic review of red ginseng, the Asian species, 4 randomized trials in type 2 diabetes. Pooled data from three placebo-controlled trials failed to favour red ginseng for fasting blood sugar (76 people; difference −0.43 mmol/L, 95% confidence interval −1.16 to 0.30). The reviewers judged the evidence "not convincing" (PMID 22139546).
What Animal and Laboratory Studies Found
Findings in this section come from animals. They show what a compound can do in a mouse and do not show that the same happens in people.
Mouse study, 2023, purified ginsenoside Rb1. The authors describe Rb1 as the principal active constituent of Panax quinquefolius. In mice of a diabetic strain fed a high-fat diet, Rb1 at 200 mg per kilogram of body weight a day lowered blood glucose, serum insulin and a calculated index of insulin resistance, and reduced injury to the pancreas. It also changed the mix of bacteria in the gut. When the mice were given antibiotics, Rb1 no longer improved their diabetes, which the authors took as a sign that the effect in mice runs through gut bacteria (PMID 36509256).
This was a single purified compound given to mice, not the whole root given to people. The records behind this page hold no laboratory enzyme or cell study of American ginseng with results that can be reported here.
Amounts Used in the Trials
The table lists what the researchers gave in each human study. These are records of what was tested. They are not doses for the reader.
| Study | Who took part | What was given | Amount | Timing or length |
|---|---|---|---|---|
| Randomized trial, 2000 | 10 adults without diabetes, 9 with type 2 diabetes | American ginseng capsules | 3 g once | 40 minutes before, or with, a 25-g glucose drink |
| Randomized trial, 2000 | 10 adults without diabetes | Ground American ginseng root | 3, 6 or 9 g once | 40, 80 or 120 minutes before a 25-g glucose drink |
| Randomized crossover trial, 2001 | 12 healthy adults | American ginseng | 1, 2 or 3 g once | 40, 20, 10 or 0 minutes before a 25-g glucose drink |
| Randomized single-blind trial, 2003 (no effect) | 12 adults without diabetes | American ginseng with 1.66% total ginsenosides | 6 g once | 40 minutes before a 75-g glucose drink |
| Comparative study, 2007 | 12 healthy adults | American ginseng root from five farms | 9 g once per visit | 40 minutes before a 75-g glucose drink |
| Randomized trial, 2015 | 13 healthy adults | Whole root and 30%, 50% and 70% alcohol extracts of American ginseng and Korean red ginseng | 3 g once per visit | 40 minutes before a 50-g glucose drink |
| Double-blind crossover trial, 2019 | 24 adults with type 2 diabetes | American ginseng extract, added to usual treatment | 1 g per meal (3 g a day) | 8 weeks |
| Double-blind placebo-controlled trial, 2013 | 64 adults with type 2 diabetes and high blood pressure | American ginseng extract, added to usual treatment | 3 g a day | 12 weeks |
| Double-blind placebo-controlled safety study, 2014 | 74 adults with type 2 diabetes | American ginseng extract with 10% ginsenosides, added to usual treatment | 3 g a day, in capsules with meals | 12 weeks |
| Randomized crossover trial, 2018 | 30 adults with type 2 diabetes completed | American ginseng with a konjac-based fibre blend | 3 g of ginseng with 6 g of fibre planned; 2.7 g of ginseng a day consumed | 12 weeks |
| Randomized controlled trial, 2021 | 80 adults with type 2 diabetes and high blood pressure | American ginseng combined with Rg3-enriched Korean red ginseng | 2.25 g a day of the combination | 12 weeks |
The preparations differ from trial to trial: ground root, whole root, alcohol extracts and extracts with a stated ginsenoside content. A result for one preparation does not transfer to another.
Safety Findings and Interactions
American ginseng reduced the effect of warfarin
Warfarin is a prescription drug that slows blood clotting. Its effect is tracked with the international normalized ratio (INR), a blood test of clotting time: a higher INR means slower clotting, and a lower INR means the warfarin is doing less.
Randomized double-blind placebo-controlled trial, 2004, American ginseng, 20 healthy volunteers. In this 4-week study all 20 took warfarin for 3 days in week 1 and again in week 4. From week 2 they were assigned to American ginseng or placebo. After 2 weeks of ginseng, peak INR was significantly lower than with placebo (difference −0.19, 95% confidence interval −0.36 to −0.07, P = 0.0012). The INR measured over time, the peak level of warfarin in the blood and the total exposure to warfarin were also significantly lower in the ginseng group. The authors concluded that American ginseng reduces warfarin's anticoagulant effect, and noted as a limit that the participants were young, healthy volunteers and not patients taking warfarin as treatment. The abstract does not state the amount of ginseng given (PMID 15238367).
A lower warfarin effect means less protection against the blood clots the drug is prescribed to prevent.
A 2017 systematic review of nine randomized trials of herbs taken with warfarin reached the same reading for this species: American ginseng altered the measured effect of warfarin, while ginseng and Korean red ginseng did not significantly alter it. The reviewers rated most of the nine trials as unclear in risk of bias and low in methodological quality, and reported that adverse events were few and none was major (PMID 28797065).
Low blood sugar
Anything that lowers blood sugar adds to the effect of insulin and of sulfonylurea drugs, both of which can cause low blood sugar (hypoglycemia) on their own. The signs of low blood sugar are shakiness, sweating, a fast heartbeat and confusion, and at lower levels seizure or loss of consciousness.
None of the abstracts behind this page gives a count of low blood sugar episodes. The authors of the 2000 trial raised the question for people without diabetes, writing that "to prevent unintended hypoglycemia it may be important that the American ginseng be taken with the meal" (PMID 10761967).
Safety measurements in the 8-week and 12-week trials
- Double-blind randomized placebo-controlled safety study, 2014, 74 adults with well-controlled type 2 diabetes. Thirty-five took an American ginseng extract containing 10% ginsenosides (3 g a day) and 39 took placebo for 12 weeks, on top of their usual treatment. Tests of kidney function, liver function and blood clotting, including INR, did not change with either treatment, and the number and severity of adverse events did not differ between ginseng and placebo (PMID 24891873).
- The 8-week crossover trial of 2019 reported that liver and kidney safety measures were unaffected (PMID 29478187).
- The 12-week trial of the two species combined reported that no adverse safety outcomes were observed (PMID 34803424).
These are findings over 8 to 12 weeks in fewer than 100 people per trial. They do not describe longer use.
Two of the trials described above also found lower systolic blood pressure with American ginseng extract than with placebo, in people who stayed on their usual treatment.
Facts that apply to every herb studied for blood sugar
- Type 1 diabetes is a state of absolute insulin deficiency. No herb, food or diet replaces insulin. Without insulin, diabetic ketoacidosis develops, and it is fatal if untreated.
- Ginseng products vary in species, plant part, extract and ginsenoside content from one product to the next. The 2012 review states that the high variability in ginsenosides may result in just as high variability in the effect of over-the-counter ginseng products (PMID 23390846).
- The research records behind this page contain no data on American ginseng in pregnancy, during breastfeeding or in children.
Limits of the Evidence
- The trials are small. The single-occasion tests had 10 to 13 adults without diabetes each, and only 9 people with type 2 diabetes took part in any of them. The one longer trial whose abstract reports HbA1c for American ginseng alone had 24 participants.
- The trials are short. No trial ran longer than 12 weeks. None of the abstracts reports on diabetes complications such as eye, kidney or nerve damage.
- A glucose drink is not a meal. The single-occasion tests used 25, 50 or 75 g of glucose in liquid form. The abstracts report no test with ordinary food.
- Batches differ. One batch had no effect, and in the five-farm study 40% of batches did not lower blood sugar by the expected amount (PMID 12571655, PMID 18066131). The ginsenoside profile that works is unknown.
- The HbA1c findings disagree. Single trials reported HbA1c 0.29% lower with American ginseng extract and 0.31% and 0.35% lower with combinations. The pooled analyses found no significant effect on HbA1c overall, and they mix species, so a pooled figure for "ginseng" is not a figure for American ginseng.
- Every longer trial added ginseng to usual treatment. None compared American ginseng with a diabetes drug, and none tested it as a replacement for medication.
- Independent replication is limited. Nearly all of the American ginseng trials cited here share authors.
Key Research Papers
- Vuksan V, Sievenpiper JL, Koo VY, Francis T, Beljan-Zdravkovic U, Xu Z, et al. American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus. Arch Intern Med. 2000;160(7):1009-13. PubMed PMID: 10761967
- Vuksan V, Stavro MP, Sievenpiper JL, Koo VY, Wong E, Beljan-Zdravkovic U, et al. American ginseng improves glycemia in individuals with normal glucose tolerance: effect of dose and time escalation. J Am Coll Nutr. 2000;19(6):738-44. PubMed PMID: 11194526
- Vuksan V, Sievenpiper JL, Wong J, Xu Z, Beljan-Zdravkovic U, Arnason JT, et al. American ginseng (Panax quinquefolius L.) attenuates postprandial glycemia in a time-dependent but not dose-dependent manner in healthy individuals. Am J Clin Nutr. 2001;73(4):753-8. PubMed PMID: 11273850
- Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V. Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia. Eur J Clin Nutr. 2003;57(2):243-8. PubMed PMID: 12571655
- Dascalu A, Sievenpiper JL, Jenkins AL, Stavro MP, Leiter LA, Arnason JT, et al. Five batches representative of Ontario-grown American ginseng root produce comparable reductions of postprandial glycemia in healthy individuals. Can J Physiol Pharmacol. 2007;85(9):856-64. PubMed PMID: 18066131
- De Souza LR, Jenkins AL, Jovanovski E, Rahelić D, Vuksan V. Ethanol extraction preparation of American ginseng (Panax quinquefolius L) and Korean red ginseng (Panax ginseng C.A. Meyer): differential effects on postprandial insulinemia in healthy individuals. J Ethnopharmacol. 2015;159:55-61. PubMed PMID: 25446600
- Vuksan V, Xu ZZ, Jovanovski E, Jenkins AL, Beljan-Zdravkovic U, Sievenpiper JL, et al. Efficacy and safety of American ginseng (Panax quinquefolius L.) extract on glycemic control and cardiovascular risk factors in individuals with type 2 diabetes: a double-blind, randomized, cross-over clinical trial. Eur J Nutr. 2019;58(3):1237-1245. PubMed PMID: 29478187
- Mucalo I, Jovanovski E, Rahelić D, Božikov V, Romić Z, Vuksan V. Effect of American ginseng (Panax quinquefolius L.) on arterial stiffness in subjects with type-2 diabetes and concomitant hypertension. J Ethnopharmacol. 2013;150(1):148-53. PubMed PMID: 23973636
- Mucalo I, Jovanovski E, Vuksan V, Božikov V, Romić Z, Rahelić D. American Ginseng Extract (Panax quinquefolius L.) Is Safe in Long-Term Use in Type 2 Diabetic Patients. Evid Based Complement Alternat Med. 2014;2014:969168. PubMed PMID: 24891873
- Jenkins AL, Morgan LM, Bishop J, Jovanovski E, Jenkins DJA, Vuksan V. Co-administration of a konjac-based fibre blend and American ginseng (Panax quinquefolius L.) on glycaemic control and serum lipids in type 2 diabetes: a randomized controlled, cross-over clinical trial. Eur J Nutr. 2018;57(6):2217-2225. PubMed PMID: 28687934
- Jovanovski E, Smircic-Duvnjak L, Komishon A, Au-Yeung FR, Sievenpiper JL, Zurbau A, et al. Effect of coadministration of enriched Korean Red Ginseng (Panax ginseng) and American ginseng (Panax quinquefolius L) on cardiometabolic outcomes in type-2 diabetes: A randomized controlled trial. J Ginseng Res. 2021;45(5):546-554. PubMed PMID: 34803424
- Shishtar E, Sievenpiper JL, Djedovic V, Cozma AI, Ha V, Jayalath VH, et al. The effect of ginseng (the genus panax) on glycemic control: a systematic review and meta-analysis of randomized controlled clinical trials. PLoS One. 2014;9(9):e107391. PubMed PMID: 25265315
- Gui QF, Xu ZR, Xu KY, Yang YM. The Efficacy of Ginseng-Related Therapies in Type 2 Diabetes Mellitus: An Updated Systematic Review and Meta-analysis. Medicine (Baltimore). 2016;95(6):e2584. PubMed PMID: 26871778
- Jafari A, Mardani H, Abbastabar M, Mehdipoor F, Parsi Nezhad B, Kordkatuli K, et al. The effect of ginseng supplementation on CVD risk factors: a comprehensive systematic review and dose-response meta-analysis. Br J Nutr. 2025;134(7):529-577. PubMed PMID: 40923100
- Kim S, Shin BC, Lee MS, Lee H, Ernst E. Red ginseng for type 2 diabetes mellitus: a systematic review of randomized controlled trials. Chin J Integr Med. 2011;17(12):937-44. PubMed PMID: 22139546
- Mucalo I, Rahelić D, Jovanovski E, Bozikov V, Romić Z, Vuksan V. Effect of American ginseng (Panax quinquefolius L.) on glycemic control in type 2 diabetes. Coll Antropol. 2012;36(4):1435-40. PubMed PMID: 23390846
- Yuan CS, Wei G, Dey L, Karrison T, Nahlik L, Maleckar S, et al. Brief communication: American ginseng reduces warfarin's effect in healthy patients: a randomized, controlled Trial. Ann Intern Med. 2004;141(1):23-7. PubMed PMID: 15238367
- Choi S, Oh DS, Jerng UM. A systematic review of the pharmacokinetic and pharmacodynamic interactions of herbal medicine with warfarin. PLoS One. 2017;12(8):e0182794. PubMed PMID: 28797065
- Zhou R, He D, Zhang H, Xie J, Zhang S, Tian X, et al. Ginsenoside Rb1 protects against diabetes-associated metabolic disorders in Kkay mice by reshaping gut microbiota and fecal metabolic profiles. J Ethnopharmacol. 2023;303:115997. PubMed PMID: 36509256